Surmodics Launches New Division to Continue Biocoat Legacy
Surmodics has officially introduced a new division named Surmodics Services & Technologies, designed to uphold the legacy of Biocoat’s operations. This launch follows the merger with Surmodics and the divestiture of certain assets associated with the transaction. The new division will operate under its own identity within the Surmodics organization, focusing on services that were core to Biocoat.
New Division to Support Medical Device Manufacturers
Located in Horsham, Pennsylvania, Surmodics Services & Technologies will continue to offer advanced hydrophilic and specialty coating technologies. Additionally, the division will provide development and engineering services to medical device manufacturers globally. Company officials emphasize that this new structure aims to create a streamlined and customer-focused organization, enhancing collaboration with device makers throughout the entire product lifecycle.
The Project Development and Engineering team at Surmodics Services & Technologies brings extensive experience, supporting projects from early-stage concepts to full commercial production. This expertise positions the division as a vital partner for medical device innovation.
The Horsham facility is equipped with scalable capabilities, catering to a wide range of clients, from start-ups to large original equipment manufacturers. Services available include formulation development, feasibility testing, process optimization, and high-volume coating production.
Focus on Agility and Innovation
According to Chip Hance, CEO of Surmodics, the launch marks a significant milestone for the company. Hance stated, “Today marks a significant milestone for our organization and for the customers we serve.” He highlighted that the division reflects a commitment to agility, innovation, and scientific expertise while fostering close collaboration with medical device manufacturers.
Surmodics Services & Technologies is expected to play a crucial role in advancing next-generation medical devices. As manufacturers increasingly seek dependable partners who can expedite development while adhering to rigorous performance and quality standards, this division aims to meet those demands effectively.
This strategic move reinforces Surmodics’ dedication to maintaining its legacy and continuing to support innovations in the medical device industry, ensuring that high standards are upheld in product development.
